Inhibition of ovarian cancer by RGD-P125A-endostatin-Fc fusion proteins

International Journal of Cancer

Volumn 129, Issue 3, 2011, Pages 751-761

  Jing, Yawu ^a   Lu, Huarui ^b   Wu, Kailang ^a   Subramanian, Indira V ^a   Ramakrishnan, S ^a,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Bevacizumab; Fc fusion protein; mutant endostatin; ovarian cancer; tumor angiogenesis

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; ENDOSTATIN ARGINYLGLYCYLASPARTIC ACID FC FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG POTENTIATION; ENDOTHELIUM CELL; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; INHIBITION KINETICS; MAMMAL CELL; MOLECULAR CLONING; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL MOVEMENT; ENDOSTATINS; FEMALE; HALF-LIFE; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; MICE; MICE, NUDE; OLIGOPEPTIDES; POINT MUTATION; RECOMBINANT FUSION PROTEINS;

EID: 79958053986     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25932     Document Type: Article

References (34)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM,. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Ozols RF,. Gynecologic Oncology Group (GOG-USA) trials in ovarian cancer. Adv Exp Med Biol 2008; 622: 131-43.
3. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009; 27: 1419-25.
4. Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J,. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004; 22: 3120-5. (Pubitemid 41103725)
5. Kandalaft LE, Motz GT, Busch J, Coukos G,. Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin. Curr Top Microbiol Immunol, in press.
6. Ramakrishnan S, Subramanian IV, Yokoyama Y, Geller M,. Angiogenesis in normal and neoplastic ovaries. Angiogenesis 2005; 8: 169-82. (Pubitemid 41712846)
7. Hanahan D, Folkman J,. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-64. (Pubitemid 26272076)
8. Stone RL, Sood AK, Coleman RL,. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol 2010; 11: 465-75.
9. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP, Ferrara N,. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007; 25: 911-20. (Pubitemid 47236916)
10. Cao Y,. Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol 2001; 33: 357-69. (Pubitemid 32324004)
11. Kumaran GC, Jayson GC, Clamp AR,. Antiangiogenic drugs in ovarian cancer. Br J Cancer 2009; 100: 1-7.
12. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J,. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85. (Pubitemid 28015876)
13. Wickstrom SA, Alitalo K, Keski-Oja J,. Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res 2002; 62: 5580-9.
14. Rehn M, Veikkola T, Kukk-Valdre E, Nakamura H, Ilmonen M, Lombardo C, Pihlajaniemi T, Alitalo K, Vuori K,. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA 2001; 98: 1024-9. (Pubitemid 32121180)
15. Yokoyama Y, Ramakrishnan S,. Addition of integrin binding sequence to a mutant human endostatin improves inhibition of tumor growth. Int J Cancer 2004; 111: 839-48. (Pubitemid 39096232)
16. Kontermann RE,. Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs 2009; 23: 93-109.
17. Jazayeri JA, Carroll GJ,. Fc-based cytokines: prospects for engineering superior therapeutics. BioDrugs 2008; 22: 11-26. (Pubitemid 351158531)
18. Wild R, Ramakrishnan S, Sedgewick J, Griffioen AW,. Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density. Microvasc Res 2000; 59: 368-76. (Pubitemid 30322264)
19. Lee TY, Tjin Tham Sjin RM, Movahedi S, Ahmed B, Pravda EA, Lo KM, Gillies SD, Folkman J, Javaherian K,. Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy. Clin Cancer Res 2008; 14: 1487-93. (Pubitemid 351413933)
20. Subramanian IV, Bui Nguyen TM, Truskinovsky AM, Tolar J, Blazar BR, Ramakrishnan S,. Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival. Cancer Res 2006; 66: 4319-28.
21. Subramanian IV, Ghebre R, Ramakrishnan S,. Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice. Gene Ther 2005; 12: 30-8. (Pubitemid 40090042)
22. Folkman J,. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 2006; 312: 594-607. (Pubitemid 43290336)
23. Lo KM, Sudo Y, Chen J, Li Y, Lan Y, Kong SM, Chen L, An Q, Gillies SD,. High level expression and secretion of Fc-X fusion proteins in mammalian cells. Protein Eng 1998; 11: 495-500. (Pubitemid 28347259)
24. Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T, Mitsuya H, Byrn RA, Lucas C, Wurm FM, Groopman JE, Broder S, Smith DH,. Designing CD4 immunoadhesins for AIDS therapy. Nature 1989; 337: 525-31. (Pubitemid 19045536)
25. Bagri A, Berry L, Gunter B, Singh M, Kasman I, Damico LA, Xiang H, Schmidt M, Fuh G, Hollister B, Rosen O, Plowman GD,. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin Cancer Res 2010; 16: 3887-900.
26. Shojaei F, Ferrara N,. Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res 2008; 68: 5501-4.
27. Francia G, Emmenegger U, Kerbel RS,. Tumor-associated fibroblasts as "Trojan Horse" mediators of resistance to anti-VEGF therapy. Cancer Cell 2009; 15: 3-5.
28. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, Kaminker J, Ferrara N,. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009; 15: 21-34.
29. Liu BY, Soloviev I, Chang P, Lee J, Huang X, Zhong C, Ferrara N, Polakis P, Sakanaka C,. Stromal cell-derived factor-1/CXCL12 contributes to MMTV-Wnt1 tumor growth involving Gr1+CD11b+ cells. PLoS One 2010; 5: e8611.
30. Ferrara N,. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 2010; 21: 21-6.
31. Chung AS, Lee J, Ferrara N,. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010; 10: 505-14.
32. te Velde EA, Reijerkerk A, Brandsma D, Vogten JM, Wu Y, Kranenburg O, Voest EE, Gebbink M, Borel Rinkes IH,. Early endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells. Br J Cancer 2005; 92: 729-35. (Pubitemid 40460610)
33. Lakatosova-Andelova M, Duskova M, Lucansky V, Paral P, Vonka V,. Effects of endostatin production on oncogenicity and metastatic activity of HPV16-transformed mouse cells: role of interleukin 1alpha. Int J Oncol 2009; 35: 213-22.
34. Szentirmai O, Baker CH, Bullain SS, Lin N, Takahashi M, Folkman J, Mulligan RC, Carter BS,. Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigation. J Neurosurg 2008; 108: 979-88. (Pubitemid 351656847)